Live attenuated Japanese encephalitis virus; Yellow fever virus + Yellow fever virus; Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus; Yellow fever virus + Live attenuated Japanese encephalitis virus; Yellow fever virus
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis, Yellow Fever
Trial Timeline
Jul 1, 2004 → Mar 1, 2007
NCT ID
NCT00982137About Live attenuated Japanese encephalitis virus; Yellow fever virus + Yellow fever virus; Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus; Yellow fever virus + Live attenuated Japanese encephalitis virus; Yellow fever virus
Live attenuated Japanese encephalitis virus; Yellow fever virus + Yellow fever virus; Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus; Yellow fever virus + Live attenuated Japanese encephalitis virus; Yellow fever virus is a phase 2 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00982137. Target conditions include Japanese Encephalitis, Yellow Fever.
What happened to similar drugs?
2 of 20 similar drugs in Japanese Encephalitis were approved
Approved (2) Terminated (0) Active (18)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00982137 | Phase 2 | Completed |
Competing Products
20 competing products in Japanese Encephalitis